logo
Plus   Neg
Share
Email

Roche Reports Positive Data From Phase III IMpower110 Study With Tecentriq

Roche (RHHBY.PK) said a Phase III IMpower110 study evaluating Tecentriq as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine in advanced non-squamous and squamous non-small cell lung cancer met its primary endpoint in an interim analysis showing that Tecentriq monotherapy demonstrated a statistically significant overall survival. Roche said it will now submit the data to global health authorities, including the FDA and EMA.

Also, the company announced that a full pivotal phase III study to treat neuromyelitis optica spectrum disorder showed that satralizumab monotherapy achieved a 55% reduction in the risk of relapses compared to placebo in the overall population.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The media mogul and Billionaire Sumner Redstone passed away on Tuesday at the age of 97, his family's holding company National Amusements said in a statement on Wednesday. He was Chairman Emeritus of ViacomCBS and chief executive officer of National Amusements. Customers in the U.S. are preferring digital or touchless payment methods due to concerns arising from the COVID-19 pandemic, a survey said. According to the survey by Rapyd Financial Network, the coronavirus pandemic has raised health and safety concerns around using cash and coins, and is accelerating the pre-existing trend toward digital transactions. American Airlines has extended its offer to waive change fees for customers who purchase tickets for travel, until December 31, 2020 in response to lower travel demand due to the coronavirus pandemic. This means that the travelers need not pay penalties for changing the origin and destination cities.
Follow RTT